UCB S.A.

Despite struggling with the financial burden, Chinese firm RemeGen is pulling out all the stops for its ongoing global Phase III RemeMG study to repeat the positive safety and efficacy outcomes from

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C

The UK’s originator drugs and generics industries are at odds over a rise in the clawbacks that companies must pay the government on the sales of branded medicines to the National Health Service under

Roivant subsidiary Immunovant announced positive Phase III data for its neonatal fragment crystallizable receptor (FcRn) inhibitor batoclimab in myasthenia gravis (MG), but a key piece of the update i